Where is YiPSCELL located?

YiPSCELL is headquartered in Seoul, South Korea.

Is YiPSCELL a funded company?

YiPSCELL is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does YiPSCELL rank among its competitors?

YiPSCELL ranks 73rd amongst 231 active competitors, of which 89 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Pandorum, which secured $429K in Mar, 2026.

Who are the top competitors of YiPSCELL?

YiPSCELL's top competitors include InSphero, Pandorum and Aspen Neuroscience. Among them, Pandorum secured the most recent funding round in March, 2026.

YiPSCELL - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of IPSC-derived stem cell therapy to diagnose and treat diseases. The company produces stem cell lines derived from normal humans and patient cells and seeks innovative therapeutic solutions such as MIUChon an injectable organoid-type osteoarthritis treatment, MIUKin is a skin organoid-type cellular therapeutic agent, and MIURon a 3D nerve cellular therapeutic agent for spinal cord injury.

Website: yipscell.com
Email ID: *****@yipscell.com
Phone Number: +82 **********

Key Metrics

Founded Year

2015

Location

Seoul, South Korea

Stage

Funding Raised

Investors

Premier Partners

Ranked

73^rd among 231 active competitors

Similar Companies

InSphero & 213 more

View YiPSCELL's full profile

YiPSCELL is a funded company. YiPSCELL has 1 institutional investor.

View details of YiPSCELL's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of YiPSCELL include InSphero, Pandorum and Aspen Neuroscience. Here is the list of Top 10 competitors of YiPSCELL, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	InSphero 2009, Schlieren (Switzerland), Series D	Developer of cell based assays for drug screening	$35M	Redalpine, Venturelab & 8 others	67/100
2nd	Pandorum 2011, Bengaluru (India), Series B	Developer of regenerative medicine and 3D tissues	$51.4M	Indian Angel Network, BTB Venture & 86 others	65/100
3rd	Aspen Neuroscience 2018, San Diego (United States), Series C	Provider of genomic-based personalised pluripotent stem cell therapy	$339M	Orbimed, Revelation Partners & 22 others	65/100
4th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
5th	Eupraxia Pharmaceuticals 2012, Vancouver (Canada), Public	Sustained released formulation for osteoarthritis	$2.44M	SVB, National Research Council Canada & 2 others	62/100
6th	Ncardia 2011, The Hague (Netherlands), Series C	Company offering hiPSC based products and services for drug discovery and development	$77.4M	Epimede, Vesalius Biocapital Partners & 9 others	61/100
7th	Kenai Therapeutics 2022, San Diego (United States), Series A	Developer of allogeneic cell therapies for neurological diseases	$89M	The Column Group, Alaska Permanent Fund & 4 others	60/100
8th	TreeFrog Therapeutics 2018, Talence (France), Series B	Developer of stem cells and organoids using proprietary technology	$84.2M	XAnge, Leonard Green and Partners & 12 others	59/100
9th	Newcells Biotech 2014, Newcastle Upon Tyne (United Kingdom), Series B	Developer of induced pluripotent stem cells derived organoid models for research application	$14.4M	Mercia, Northstar Ventures & 7 others	58/100
10th	Retro 2020, San Francisco (United States), Series D	Provider of healthcare staffing services	$180M	-	57/100
73rd	YiPSCELL 2015, Seoul (South Korea), Funding Raised	Developer of IPSC-derived stem cell therapy to diagnose and treat diseases	-	Premier Partners	37/100